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ABSTRACT 
Objectives: Post-exposure prophylaxis (PEP) for HIV is often poorly tolerated, and not completed. 
Alternative PEP regimens may improve adherence and completion, aiding HIV prevention. We 
conducted an RCT of a maraviroc-based PEP regimen compared to a standard-of-care regimen using 
ritonavir–boosted lopinavir.  
Methods: Patients attending 5 UK sexual health clinics, meeting criteria for PEP were randomized, to 
Truvada® (TVD) 200/245mg OD plus Kaletra® 400/100mg or maraviroc 300mg BD. The composite 
primary end point was completion of 28 days of the allocated PEP regimen without grade 3 or 4 
clinical or laboratory adverse events (AEs) related to the PEP medication. 
Results:  213 individuals were randomised (107 to maraviroc; 106 toritonavir-boosted 
lopinavir). Follow-up rates were high in both groups. There was no difference in the primary end 
point (p=0.36) completed PEP without grade 3 or 4 AEs. Discontinuation of PEP was the same (18%) 
in both groupsThere were no grade 3 or 4 clinical AEs in either arm, but more grade 1 or 2 clinical 
AEs in the ritonavir-boosted lopinavir arm (91% vs. 70%; p< 0.001). There were somewhat more 
grade 1 or 2 laboratory abnormalities in the ritonavir-boosted lopinavir arm (64% vs 49%; p=0.056). 
Antidiarrhoeal medication use was higher in the ritonavir-boosted lopinavir arm (67% vs 25%; p< 
0.001). There were no HIV seroconversions in the study period.  
Conclusion: The completion rate in the absence of grade 3 or 4 adverse events was similar with both 
regimens. Maraviroc-based PEP was better tolerated, supporting its use as an option for non-
occupational PEP. 
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Introduction 
HIV post-exposure prophylaxis (PEP) is a well-established prevention strategy in the UK and most of 
the developed world. The current United Kingdom National Guideline for the Use of HIV Post-
Exposure Prophylaxis Following Sexual Exposure (PEPSE) recommends triple combination therapy for 
28-days, to be started as soon as possible after exposure, preferably within 24 hours, but it can be 
offered up to 72 hours after [1]. PEP should be considered when other strategies for preventing HIV 
infection have not been used or failed, and requires a risk-benefit assessment to be undertaken for 
each individual presenting following an exposure event. 
A prospective randomised-controlled trial to determine the efficacy of post-exposure prophylaxis 
following sexual exposure has been precluded due to the high number of participants that would be 
required for such a study. In addition the evidence from observational studies in favour of efficacy 
has led to a lack of the necessary equipoise. A case-control study conducted in healthcare workers 
suggested that the use of zidovudine (AZT) for post-exposure prophylaxis (PEP) after percutaneous 
exposure to HIV-infected blood was associated with a significant decrease in the risk of HIV 
transmission [2]. In addition mother to child transmission studies where only the neonate received 
antiretroviral therapy have also demonstrated a protective effect [3, 4].  Animal models mimicking 
sexual exposure either vaginally or rectally also show protective benefits of the use of antiretroviral 
therapy and demonstrate that time to initiation and duration of PEP influence outcome of PEP, with 
delays and shorter courses reducing effectiveness [5]. 
However studies also suggest that PEP is often poorly tolerated, with individuals frequently 
reporting side effects and poor completion rates [6]. As delayed initiation and non-completion of 
PEP are likely to reduce efficacy, it is important to actively manage side-effects and to choose 
regimens that are likely to be better tolerated.  
The UK guideline for the use of post-exposure prophylaxis for HIV following sexual exposure [7], at 
the time of initiation of our study, recommended tenofovir (TDF) and emtricitabine (FTC) as the fixed 
dose combination Truvada® (TVD) and ritonavir-boosted lopinavir (LPV/r - Kaletra®) for 28 days as 
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standard of care. In non-randomised comparisons PEP regimens containing TDF combined with 
lamivudine (3TC) or FTC were associated with improved completion rates and fewer treatment 
discontinuations due to adverse events, than regimens containing zidovudine (ZDV) [8,9]. The 
combination of TDF and FTC has also been shown to prevent acquisition of HIV infection when used 
as pre-exposure prophylaxis (PrEP) [10-12].   
The choice of third agent is less clear and depends on consideration of short term tolerability. It is 
well recognized that ritonavir-boosted protease inhibitors (rPI) including LPV/r are commonly 
associated with gastrointestinal side effects and elevations in blood lipids [13]. In the ABT-730 study 
conducted in HIV positive participants, 37% experienced grade 3 or 4 adverse events and laboratory 
abnormalities in the LPV/r arm [14]. LPV/r also inhibits cytochrome p450 CYP3A and therefore has 
the potential for drug-drug interactions. 
Maraviroc (MVC), a CCR5 antagonist has been shown to be an effective antiretroviral agent in the 
MOTIVATE and MERIT studies [15-18]. In MERIT the percentage of patients achieving HIV-1 RNA < 50 
copies/mL was comparable to those receiving efavirenz where they had CCR5-tropic virus at 
baseline. Also, MVC does not inhibit any of the major P450 enzymes at clinically relevant 
concentrations and appears to have fewer drug-drug interactions than LPV/r. Furthermore the 
observed frequency of grade 3 or 4 adverse events was low (20%) in the MERIT study. 
MVC acts pre-integration which may have theoretical advantages for use in both PrEP and PEP. 
Animal data demonstrates that the use of a CCR5 inhibitor reduced the likelihood of macaques 
acquiring SIV following vaginal exposure [19].  MVC has also been demonstrated to penetrate the 
male and female genital tract well and achieve high rectal tissue concentrations [20, 21]. 
We conducted an open-label, randomised controlled trial designed to determine whether a MVC-
based PEP combination was superior to a LPV/r-based combination. The comparison was based on 
the proportion of patients who complete a full PEP course in the absence of clinically important 
treatment-related toxicities. 
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Methods 
Study design and participants 
We conducted a parallel-group randomised controlled open-label trial to compare tolerability of 
MVC-based PEP relative to a LPV/r-based combination. We enrolled participants attending 5 sexual 
health clinics in England. Eligible participants were adults aged 18 years or older who were 
considered eligible for PEP for non-occupational exposure according current UK national guidelines; 
participants had to report unprotected anal or vaginal  intercourse with a known HIV positive 
partner, or a partner at high risk for HIV. Patients with a positive HIV antibody test result at 
screening, currently receiving medication with known interactions with MVC or LPV/r, pregnant or 
possibly pregnant were not eligible. If the source was known to have multi-drug resistant HIV and 
therefore more likely to have CXCR 4-tropic virus, these participants were also excluded. 
 
Ethics 
The protocol was reviewed and approved by the London-Riverside Research Ethics Committee (REC 
reference number: 11/LO/1333) and by the Medicines and Healthcare products Regulatory Agency. 
All participants provided written informed consent. The trial was registered with the International 
Standard Randomised Controlled Trial Number registry (number ISRCTN63350011). 
 
Randomisation  
Randomisation occurred on the day the patient attended the clinic requesting PEP. Participants were 
randomly assigned (1:1) to TVD, one tablet once daily in addition to either a) MVC (300 mg), one 
tablet twice daily (experimental arm) or b) LPV/r (lopinavir 200 mg, ritonavir 50 mg), two tablets 
twice daily (control arm) for 28 days. Block randomisation was undertaken, with blocks of varying 
size, stratified by centre. Randomisation was performed online; treatment allocation was open label. 
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Procedures 
All trial participants started their allocated medication on the randomisation day (baseline visit) and 
were followed according to the trial schedule which included study visits at baseline, days 14 and 28 
and month four. Study medication was dispensed at baseline and again at the day 14 visit for an 
individual to complete the full course of 28 days of PEP, according to usual clinical practice. 
Adherence to the PEP regimen was measured by self-reported completion and a count of tablets 
remaining at day 14 and day 28 visits.   All clinical and laboratory adverse events were graded 
according to the Division of AIDS table for Grading the Severity of Adult and Paediatric adverse 
events (Version 2.0, November 2014) by investigators and reported to the coordinating centre 
following standard ICH GCP Guidance.  Review of any serious adverse events was carried out by an 
independent clinical reviewer who was blinded to the study allocation. 
Switching between study arms was not allowed, but participants could be switched to alternative 
PEP regiments for safety and tolerability reasons. 
 
Outcomes 
The primary outcome was a composite end point of completion of 28 days of the allocated PEP 
regimen without grade 3 or 4 clinical or laboratory adverse events (excluding lipid abnormalities) 
related to PEP. The secondary outcomes included completion rates of 28 days of allocated PEP 
regimen, rates of grade 1, 2, 3 or 4 clinical adverse events and laboratory abnormalities; adherence 
to the allocated PEP regimen; number of doses of antidiarrhoeal and/or antiemetic medication 
taken; rates of HIV seroconversion at month 4 after exposure; number of sexual partners and 
unprotected anal/vaginal intercourse in i) while receiving PEP and ii) in the three months after 
completion of PEP with a potentially serodiscordant partner. Rates of sexually transmitted infections 
(gonorrhoea, chlamydia, lymphogranuloma venereum, syphilis, hepatitis B and C) were also 
examined at baseline and follow-up. For testing clinical adverse events were grouped by organ and 
laboratory adverse events by system.  
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For the purposes of this study, completion of allocated PEP combination to day 28 (or 14) was 
defined as not stopping the PEP combination by day 28 (or 14), irrespective of whether some doses 
were missed.  
 
 
Sample size 
We calculated that with 140 patients recruited per arm, allowing for a 75% follow-up rate, 105 
patients would provide the primary outcome in each arm. This sample size provided 80% power to 
demonstrate the superiority of MVC based PEP relative to LPV/r based PEP if in the experimental 
arm the prevalence of the primary outcome (completion of 28 days of PEP without grade 3 or 4 
toxicity) was 20% higher (70%) than the estimated rate in the control arm (50%). The sample size 
also provided 80% power if under MVC the prevalence was 79% and in the LPV/r arm it was 60%. 
Though this was not formally designed as a non-inferiority trial and no choice of non-inferiority 
margin was made, we also calculated that this sample size would provide over 80% power to 
demonstrate the non-inferiority of MVC relative to LPV/r if the prevalence of the primary outcome 
was 60% under MVC and 50% under LPV/r, or 69% under MVC and 60% under LPV/r, if non-
inferiority is defined as a prevalence not more than 10% lower than in the LPV/r arm. 
 
Primary and secondary outcome analyses 
All primary comparisons of the two PEP treatments were made according to the randomisation arm 
(intention-to-treat, ITT). All effect measures are presented with 95% confidence intervals, with p-
values based on 2-sided tests; a 5% significance level was used.  
Adjustment was made for recruiting centre and for any factors for which an imbalance between 
arms was seen at baseline or which were seen to be linked to differential loss to follow up between 
arms. Regression analysis was used; standard logistic regression for binary outcomes and ordinal 
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logistic regression for ordinal outcomes. The effect measures are odds ratios, presented with 95% 
confidence intervals; primary comparisons of arms are based on the adjusted odds ratios. 
All analyses were conducted using Stata SE version 12.0; Stata Corporation, College Station, TX, USA. 
 
Missing data 
All analyses are presented for complete cases only, except for analysis of the primary outcome 
measure which was repeated multiply imputing missing outcome values. Missing data in the primary 
outcome were anticipated, arising if a patient attended the 14 day visit and reported PEP 
compliance to that time and no grade 3 or 4 laboratory or clinical adverse events attributable to PEP, 
but then drops out. Imputation was based on data from similar patients who do not drop out after 
the 14 day visit, and conducted separately by randomisation arm. Imputation was also conducted 
separately for the two components of the primary outcome (completion of PEP, absence of grade 3 
or 4 adverse events attributable to PEP) based on logistic regression models including age as a 
predictor, as it was seen to be related to the primary outcome. Age (as a continuous variable) and 
site (3 categories) were also then adjusted for in all analyses. 
 
Results 
Between August 2012 and December 2014, 213 participants were recruited; 107 were randomised 
to TVD/MVC and 106 to TVD/LPV/r. Recruitment was discontinued early because the national 
recommended  standard of care regimen for PEP was changed to TVD/raltegravir [1].  
The primary outcome was observed for 98 participants (92% of those randomised) in each arm, and 
attendance at each study visit is displayed in Figure 1. Baseline characteristics (shown in Table 1) 
were similar between study groups. The study population was mainly male (98%), white (84%), and 
with a mean age of 33.9 (SD 9.56) years. Overall, 94% of participants were MSM. A third of the study 
population (33%) had received PEP previously. All study participants were prescribed PEP following 
high risk sexual exposure with a potentially seropositive partner.  
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There was no difference in the combined primary endpoint between study arms: 71% and 65% in the 
MVC and LPV/r arms respectively at day 28 (p=0.357). Multiple imputation of the primary outcome 
was conducted because of missing data and this provided very similar results (73% and 67%; 
p=0.330). The completion rate of PEP in the MVC arm was 82% compared to 77% in the LPV/r arm 
(p=0.350) (Table 2). By day 28 of follow-up, there were no SAEs or grade 3 or 4 clinical adverse 
events in the study population. However, there were 123 grade 1 or 2 clinical adverse events in the 
MVC arm and 175 in the LPV/r arm. Participants randomised to MVC had a significantly lower rate of 
gastro-intestinal adverse events (OR= 0.23; 95%CI= 0.22-0.42; p<0.0001) (Table 3). Therefore, a 
lower proportion of participants in the MVC arm were prescribed antidiarrhoeal medication 
(OR=0.15; 95%CI= 0.08-0.28; p<0.001) and there was somewhat lower use of antiemetic medication 
(OR=0.68; 95%CI=0.39-1.16; p=0.158) (Table 2). 
A total of 127 and 158 grade 1, 2 or 3 laboratory adverse events were observed in patients 
randomised to the MVC and the LPV/r arm respectively by day 28. Most grade 3 laboratory adverse 
events were related to renal function measurements. 13 participants had grade 3 
hypophosphatemia, but with no difference between randomisation arms. There were 57 
participants with hypercholesterolaemia  with a significant difference between randomisation arms 
(17 and 40 in patients randomised to MVC and LPV/r respectively; p<0.0001) but the only grade 3 
hypercholesterolaemia reported by day 28 was in a participant in the MVC arm, this patient had 
persistent hypercholesterolaemia during the entire study period including month 4 visit, which 
suggests that this was a pre-existing condition not related to study medication (no baseline 
cholesterol measurement was available). Laboratory abnormalities reflecting metabolic disturbances 
(lipids and glucose) were less frequently observed in participants on MVC (OR=0.27; 95%CI=0.14-
0.50; p<0.0001), and predominantly due to grade 1-2 hypertriglyceridaemia. The distribution of 
laboratory adverse events are summarised in Table 4. By 4 months after starting PEP, 93% of grade 
2, 3 and 4 laboratory adverse events were documented as having resolved. 
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Attendance at study visits was high in both groups with 80% of participants in the MVC arm and 81% 
in the LPV/r arm attending the day 28 study visit.  Adherence to the allocated PEP regimen at day 28 
was similar in both arms with 27% of participants reporting missing at least one dose of TVD, 
whereas 22% of participants missed at least one dose of MVC or LPV/r. There was no difference 
between arms in the number of days absent from work, or in the number of additional clinic visits 
during the course of PEP (Table 2).  
67% and 53% of participants in the MVC and LPV/r arms, respectively, attended their month 4 study 
visits. By the end of the study follow up there were no HIV seroconversions reported.  
At the baseline visit 12% of participants were diagnosed with a sexually transmitted infection (STI). 
At the day 28 visit, when all participants were screened for STIs again, 13% were diagnosed with an 
STI (Table 5). During the study period participants randomised to both groups showed similar sexual 
behaviour patterns. By the day 14 visit 55% and 62% in the MVC and LPV/r arms respectively 
(p=0.344) reported no sexual activity since PEP initiation (Table 6). Combining study arms we see 
that 15% of participants reported ≥3 sexual partners since baseline by day 28 and 37% reported ≥3 
sexual partners since baseline by 4 months. The proportion of participants reporting unprotected sex 
since baseline was 8% at day 28 and 26% at 4 months. 
 
Discussion 
The completion rate of PEP was high in both arms of this trial, and did not differ between arms. 
Furthermore, there were no differences observed in the rate of PEP completion in the absence of 
grade 3 or 4 clinical and laboratory adverse abnormalities comparing MVC vs. LPV/r-based 
combinations. This was the combined primary endpoint of the trial.     
The favourable MVC tolerability and safety profile, demonstrated in previous studies both in 
treatment and prevention make it an attractive option to be considered as part of a PEP regimen 
[15-18, 22]. In this study the benefit of using MVC was limited to fewer mild to moderate 
gastrointestinal side effects in the MVC-arm (OR= 0.23; 95%CI= 0.22-0.42; p<0.0001). The excess of 
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gastrointestinal symptoms in the LPV/r-arm led to increased use of anti-diarrhoeal and anti-emetic 
medication. Low completion rates of PEP have been reported in many settings; therefore PEP 
regimens with a more favourable tolerability profile may help in this regard [23-26]. Recent data 
suggest that another ritonavir-boosted PI, darunavir, may be better tolerated [27]. However all 
ritonavir-boosted PI-based combinations have a higher risk for drug-drug interactions than 
alternatives such as raltegravir or rilpivirin [28, 29].  
We did not observe any serious clinical adverse events. Laboratory abnormalities were mild to 
moderate grade 1 to 3, mostly reflecting hypertriglyceridemia and hypophosphatemia.  Laboratory 
abnormalities associated with PEP exposure were transient and returned to normal after cessation 
of PEP.  
It was decided not to include lipids in the primary end point because hyperlipidaemia is a recognized 
effect of LPV/r, which would be transient and with no clinically significant sequelae in the context of 
short-term treatment.  
The results of the study indicate that when using TVD and MVC the routine prescription of 
antiemetic or antidiarrhoeal drugs is not necessary. Where LPV/r is used, routine provision of 
antiemetic and antidiarrhoeal drugs is standard practice in the UK and this study suggests that this 
should continue to be considered. 
Although proximal renal tubular dysfunction and Fanconi’s syndrome are well reported in HIV-
positive individuals on TDF-based ART [30], these have not been reported in the setting of PEP and 
were not seen in this study. 
We recruited a high-risk population, of whom a high proportion had received PEP previously, the 
majority more than once. This may in part explain the high rate of treatment completion and 
adherence we observed. We also observed high rates of STIs, both at baseline and during the follow-
up period, but no HIV seroconversions, consistent with previous reports [31]. High risk individuals 
may be suitable candidates for pre-exposure prophylaxis rather than repeated courses of PEP [32].  
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The strengths of this trial are the low withdrawal and lost-to-follow up rates and the design being 
representative of routine clinical care. Potential limitations include the restriction of the study 
population to those at risk from sexual exposure, and almost all MSM. There were no occupational 
exposure cases. The fact that many of the participants had received PEP previously, and were 
seeking PEP again means that those who had had more severe adverse effects of current PEP 
regimens may have been less likely to be seek PEP again, and so be less likely to be included in the 
study. Previous users of these medications may also have a different perception of the adverse 
effects.  Although at the close of recruitment 213 participants out of an initial planned sample size of 
280 had been enrolled, due to a change in the standard of care regimen, we had a better than 
expected follow-up rate. We had 196 participants who provided data for the primary outcome, 
which is only just short of the planned 210 and did not therefore materially compromise the power 
of the study. 
In conclusion, MVC-based PEP has demonstrated advantages in comparison with a LPV/r-based PEP 
regimen in terms of tolerability, even if that did not translate into a significant increase in 
completion rates in this trial. 
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Figure 1: Trial profile 
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Table 1: Baseline demographic and sexual behaviour characteristics of the sample 
 
Characteristics,          
n (%) or mean (SD)  
 MVC arm 
N=107 
LPV/r arm 
N=106 
Age in years, mean 
(SD) 
 33.6 (9.15) 34.4 (10.0) 
Sex Female 4(4) 1(1) 
Male 103(96) 105(99) 
Ethnicity Black 4 (4) 3 (3) 
South Asian 1 (1) 4 (4) 
Other/mixed 10 (10) 10 (10) 
White 86 (85) 85 (83) 
Sexual orientation Bisexual 12(12) 10(10) 
Heterosexual 6(6) 4(4) 
Homosexual 83(82) 89(86) 
Number of sex 
partners in the last 3 
months 
No Sex 0(0) 0(0) 
1 9(9) 20(20) 
2 17(17) 19(19) 
3-9 42(43) 34(34) 
10+ 30(31) 26(27) 
Previous PEP No 70(69) 62(60) 
Yes 32(31) 41(40) 
Number of times had 
PEP previously 
1 16(50) 25(61) 
2+ 16(50) 16(39) 
Had STI screen at 
baseline 
No  71(68) 57(54) 
Yes 33(32) 48(46) 
Any STIs at baseline 
visit if screened 
No 29(88) 42(88) 
Yes 4(12) 6(13) 
Syphilis at baseline if 
tested 
No 29(100) 28(97) 
Yes 0(0) 1(3) 
19 
 
Table 2: Outcome measures, summary statistics and odds ratios (OR) comparing MVC with LPV/r arm  
Outcome measure,                  
N=denominator across arms 
 MVC arm  
n(%),N=107 
LPV/r arm 
n(%),N=106 
1p-value Unadjusted 2                        
OR (95% CI) 
3Adjusted 2                                      
OR (95% CI) 
     p=0.357 p=0.254 
Primary: completion of 28 days of 
allocated PEP regimen without grade 3 or 
4 clinical or laboratory adverse event 
related to PEP, N=196 
No       
Yes 
28(29)         
70(71) 
34(35)         
64(65) 
0.357 1.33 (0.73-2.43) 1.44 (0.77-2.70) 
     p=0.330 p=0.262 
Primary after imputation: completion of 
28 days of allocated PEP regimen without 
grade 3 or 4 clinical or laboratory adverse 
event related to PEP, N=213 
No       
Yes 
27%                 
73% 
33%                
67% 
0.350 1.35 (0.74-2.46) 1.43 (0.77-2.65) 
     p=0.352 p=0.309 
Completion of 28 days of allocated PEP 
regimen, N=193 
No      
Yes 
17(18)          
80(82) 
22(23)        
74(77) 
0.351 1.40 (0.69-2.84) 1.46 (0.70-3.04) 
     p=0.056 p=0.079 
Laboratory abnormalities, highest grade 
reported, N=196 
0            
1            
2            
3 
37(37)         
29(29)         
20(20)         
13(13) 
23(24)        
30(31)         
31(33)        
13(12) 
0.108 0.61 (0.37-1.01) 0.63 (0.38-1.05) 
     p=0.957                    
0.98 (0.42-2.30) 
p=0.911                          
0.95 (0.39-2.29) Grade 3+ laboratory abnormality related 
to PEP, N=196 
No 87 (88) 85 (88) 0.957 
Yes 12(12) 12(12)  
     p<0.001 p<0.001 
Clinical adverse events, highest grade 
reported, N=196 
0            
1            
2 
30(30)          
59(60)         
10(10) 
9(9)             
69(71)        
19(20) 
0.001 0.32 (0.17-0.59) 0.32(0.17-0.59) 
     p=0.502 p=0.514 
Number of missed doses of TVD over 14 
days, if completed 14 days of allocated 
PEP regimen, N=184 
0          
1+ 
89(95)              
5(5) 
83(92)            
7(8) 
0.493 0.67 (0.20-2.18) 0.67 (0.20-2.22) 
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     p=0.190 p=0.123 
Number of missed doses of TVD over 28 
days, if completed 28 days of allocated 
PEP regimen, N=154 
0          
1+ 
68(85)          
12(15) 
68(92)            
6(8) 
0.178 2.00 (0.71-5.64) 2.31 (0.80-6.68) 
     p=0.409 p=0.384 
Number of missed doses of LPV/r or  
MVC over 14 days if completed 14 days 
of allocated PEP regimen, N=184 
0            
1           
2+ 
80(85)         
12(13)              
2(2) 
73(81)        
11(12)            
6(7) 
0.865 0.72 (0.33-1.56) 0.71 (0.33-1.54) 
     p=0.829 p=0.867 
Number of missed doses of LPV/r or MVC 
over 28 days, if completed 28 days of 
allocated PEP regimen, N=154 
0            
1          
2+ 
62(78)            
8(10)            
10(12) 
58(78)          
9(12)            
7(10) 
0.853 1.09 (0.51-2.32) 1.07 (0.50-2.28) 
     p<0.001 p<0.001 
Number of doses of antidiarrheal 
medication taken over 28 days, N=196 
0           
1-5       
6+ 
74(75)          
18(18)              
7(7) 
32(33)         
28(29)         
37(38) 
<0.001 0.16 (0.09-0.28) 0.15 (0.08-0.28) 
     p=0.157 p=0.158 
Number of doses of antiemetic taken 
over 28 days, N=196 
0           
1-5       
6+ 
58(59)         
22(22)         
19(19) 
49(51)         
20(21)         
28(29) 
0.059 0.68 (0.39-1.16) 0.68 (0.39-1.16) 
     p=0.905 p=0.863 
Number of days absent from work or 
college over 28 days (not including days 
absent for clinic visits), N=173 
0           
1-5       
6+ 
77(87)              
5(6)                  
7(8) 
73(87)            
6(7)                 
5(6) 
0.843 1.05 (0.44-2.53) 1.08 (0.45-2.61) 
       
HIV seroconversion 4 months after 
exposure, N=119 
No      
Yes  
66(100)           
0(0) 
53(100)           
0(0) 
1.000 - - 
     p=0.449 p=0.338 
Additional Visits, N=196 No 88(90) 91(93) 0.446   1.48 (0.54-4.05) 1.67 (0.58- 4.90) 
 Yes 10(10) 7(7)  
1Chi squared, Fisher exact and Mann-Whitney tests were used as appropriate. 
2 Odds ratios based on logistic regression for binary outcome or ordinal logistic regression assuming proportional odds for ordinal outcome. 
3Adjusted for age (continuous) and site
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Table 3: Clinical Adverse events (CAE) by the highest grade at 28 days visit, by study arm 
CAE type MVC arm n(%),N=99 LPV/r arm n(%),N=97 1OR (95% CI),               
p-value 
Grade 0 1 2 0 1 2  
CNS 85(86) 12(12) 2(2) 79(81) 17(18) 1(1) 0.68 (0.31-1.48), 
p=0.330 
Headache 89(90) 8 (8) 2 (2) 83(86) 13(13) 1(1)  
Sleeping 
disorder 
93 (94) 6 (6) 0(0) 91 (94) 6 (6) 0(0)  
Other CNS 97 (98) 2 (2) 0(0) 96 (99) 1(1) 0(0)  
GI 46(47) 46(47) 6(6) 14(14) 68(70) 15 
(16) 
0.32 (0.18-0.56), 
p<0.0001 
Nausea/vomiting 69(70) 27(27) 3(3) 59 (61) 31 (32) 7 (7)  
Diarrhoea 80(81) 18(18) 1(1) 25(26) 61(63) 11(11)  
Constipation 95(96) 3(3) 1(1) 95(98) 2(2) 0(0)  
Other GI 83(84) 15(15) 1(1) 60(62) 30(31) 7(7)  
Skin 96 (97) 3 (3) 0(0) 88(91) 8 (8) 1 (1) 0.36 (0.09-1.38) 
p=0.135 
Rash 97(98) 2(2) 0(0) 89(92) 7(7) 1(1)  
Other skin 98(99) 1(1) 0(0) 96(99) 1(1) 0(0)  
Tiredness, 
fatigue, etc. 
63 (64) 30 (30) 6 (6) 59 (61) 35 (36) 3 (3) 1.05 (0.58-1.87) 
p=0.882 
Other 81 (82) 14 (14) 4 (4) 70 (72) 24 (25) 3 (3) 0.59(0.30-1.16) 
p=0.128 
1 OR for MVC arm relative to LPV/r. Ordered Logistic regression assuming proportional odds for GI (grade 0, 1, 2). Logistic regression for 
CNS, Skin, Tiredness, Other (binary outcome grade 1+) 
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Table 4:  Laboratory Adverse events (LAE) by the highest grade at 28 days visit, by study arm. 
LAE type MVC arm n(%), N=99 LPV/r arm                                       
n(%), N=97 
2OR (95% CI),     
p-value 
Grade 0 1 2 3 0 1 2 3  
Renal 45(45) 23(23) 19(19) 12(12) 46(47) 21(22) 19(20) 11(11) 1.06 (0.63-1.78), 
p=0.820 
Sodium  94(96) 4(4) 1(1) 0(0) 95(98) 2(2) 0(0) 0(0)  
Urea  92(93) 0(0) 0(0) 7(7) 9598) 0(0) 0(0) 2(2)  
Creatinine  98(99) 1(1) 0(0) 0(0) 97(100) 0(0) 0(0) 0(0)  
1Phosphate 
(see notes) 
66(67) 13(13) 16(1) 4(4) 56(58) 14(14) 18(19) 9(9)  
UPCR 82(83) 14(14) 2(2) 1(1) 89(86) 9(9) 2(2) 0(0)  
Liver 83(84) 13(13) 2(2) 1(1) 82(85) 12(12) 3(3) 0(0) 1.05(0.49-2.27), 
p=0.894 
Bilirubin 89(90) 8(8) 1(1) 1(1) 88(91) 7(7) 2(2) 0(0)  
ALT  93(94) 5(5) 1(1) 0(0) 90(93) 6(6) 1(1) 0(0)  
Metabolic 76(77) 20(20) 1(1) 2(2) 47(49) 28(29) 21(22) 1(1) 0.27(0.14-0.50), 
p<0.0001 
Glucose  95(96) 4(4) 0(0) 0(0) 89(92) 7(7) 1(1) 0(0)  
Total 
cholesterol 
82(83) 14(14) 2(2) 1(1) 57(59) 20(21) 20(21) 0(0)  
LDL 90(91) 8(8) 0(0) 1(1) 78(80) 12(12) 6(6) 1(1)  
Triglyceride 94(95) 5(5) 0(0) 0(0) 73(75) 22(23) 2(2) 0(0)  
Bone 65(66) 14(14) 16(16) 4(4) 55(57) 15(15) 18(19) 9(9) 0.66 (0.38-1.15), 
p=0.145 
1Phosphate 66(67) 13(13) 16(16) 4(4) 56(58) 14(14) 18(19) 9(9)  
Calcium 98(99) 1(1) 0(0) 0(0) 95(99) 2(2) 0(0) 0(0)  
1 Phosphate results contribute to both Renal and Bone groups 2 OR for MVC arm relative to LPV/r. Ordered Logistic regression assuming 
proportional odds for Renal (grade 0, 1, 2, 3), Metabolic (grade 0, 1, 2+), Bone (grade 0, 1, 2+). Logistic regression for liver (binary outcome 
grade 1+) 
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Table 5: 1STIs - rates of testing and infection, by study arm 
Variables  MVC arm 
n(%) 
LPV/r arm 
n(%) 
Had STI screen at 14 days, n=191 No 28(29) 29(30) 
Yes 69(71) 66(70) 
Any STIs at 14 days visit if 
screened, n=134 
No 57(84) 57(86) 
Yes 11(16) 9(14) 
Syphilis at 14 days if tested, n=52 No 26(100) 26(100) 
Yes 0(0) 0(0) 
Had STI screen at 28 days, n=172 No 57(67) 54(64) 
Yes 28(33) 31(36) 
Any STIs at 28 days visit if 
screened, n=59 
No 23(82) 28(90) 
Yes 5(18) 3(10) 
Syphilis at 28 days if tested, n=49 No 23(100) 26(100) 
Yes 0(0) 0(0) 
Had STI screen at 4 moths, n=120 No 28 (42) 32(59) 
Yes 38(58) 22(41) 
Any STIs at 4 months visit if 
screened, n=60 
No 38(100) 22(100) 
Yes 0(0) 0(0) 
Syphilis at 4 months if tested, n=25 No 12(100) 10(8) 
Yes 0(0) 3(23) 
1STI screen may include at least one of the following tests: Chlamydia Trachomatis (CT) (up to 3 sites), gonococcus (GC) (up to 3 sites), 
Lymphogranuloma venereum (LGV) (up to 3 sites), herpes, human papilloma virus (HPV), bacterial vaginosis (BV), non-specific urethritis 
(NSU), and syphilis. 
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Table 6: Sexual behaviour characteristics at follow up visits, by study arm 
Variables  MVC arm 
MVC arm 
n(%) 
LPV/r arm 
LPV/r arm 
n(%) 
Number of sex partners since 
baseline reported at 14 days visit, 
n=188 
No sex 53(55) 57 (62) 
1 3 (31) 25 (27) 
2 7(7) 5(5) 
3-9 5(5) 5(5) 
10+ 1(1) 0(0) 
Number of sex partners since 
baseline reported at 28 days visit, 
n=172 
No sex 35(41) 44(51) 
1 32(37) 24(28) 
2 6(7) 6(7) 
3-9 12(14) 11(13) 
10+ 1(1) 1(1) 
Number of sex partners since 
baseline reported at 4 months 
days visit, n=125 
No sex 13(19) 12(23) 
1 21(30) 14(25) 
2 9 (13) 10(18) 
3-9 15(21) 12(22) 
 10+ 12(17) 7(13) 
Unprotected sex since baseline 
reported at 14 days, n=191 
No 88 (92) 88(93) 
Yes 8(8) 4(4) 
Don’t know 0(0) 3(3) 
Unprotected sex since baseline 
reported at 28 days, n=172 
No 78(91) 80(93) 
Yes 8(9) 6(7) 
Don’t know 0(0) 0(0) 
Unprotected sex since baseline 
reported at 4 months, n=126 
No 49(70) 43(77) 
Yes 21(30) 12(21) 
Don’t know 0(0) 1(2) 
 
 
 
 
 
 
 
 
 
 
